DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 115 filers reported holding DENALI THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $45,000 | -30.8% | 1,524 | -24.7% | 0.00% | – |
Q1 2022 | $65,000 | -83.8% | 2,024 | -77.6% | 0.00% | -100.0% |
Q4 2021 | $402,000 | +219.0% | 9,024 | +261.0% | 0.00% | +100.0% |
Q3 2021 | $126,000 | -73.5% | 2,500 | -58.7% | 0.00% | -66.7% |
Q2 2021 | $475,000 | +691.7% | 6,053 | +474.8% | 0.00% | – |
Q1 2021 | $60,000 | -33.3% | 1,053 | -1.6% | 0.00% | -100.0% |
Q4 2020 | $90,000 | +125.0% | 1,070 | -53.8% | 0.00% | – |
Q4 2019 | $40,000 | +14.3% | 2,316 | 0.0% | 0.00% | – |
Q3 2019 | $35,000 | -27.1% | 2,316 | 0.0% | 0.00% | – |
Q2 2019 | $48,000 | -11.1% | 2,316 | 0.0% | 0.00% | – |
Q1 2019 | $54,000 | +12.5% | 2,316 | 0.0% | 0.00% | – |
Q4 2018 | $48,000 | – | 2,316 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |